Zacks Investment Research
13 May 2026, 22:36 UTC · 26w ago
Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates
Impact · against what's priced in
AYTU shares face downward pressure following a significant earnings miss and a substantial year-over-year revenue decline. While the company slightly beat revenue estimates, the widening loss of $0.53 per share and a pattern of missing EPS estimates for four straight quarters suggest deteriorating fundamentals.
- AYTU−0.60
No priced-in read yet
- In context
The company reported a quarterly loss of $0.53 per share, significantly missing the $0.31 loss estimate, and revenue fell to $12.41 million from $18.45 million a year ago.
Read from the article alone

Search tags



